PF-Atlas › Clinical Trials › NCT03451045
Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
Lenabasum 20 mg · Phase 2
Registry ID
NCT03451045
Phase
Phase 2
Status
Completed
Drug / intervention
Lenabasum 20 mg
Sponsor
Corbus Pharmaceuticals Inc.
Start
2017-12-22
Enrollment
447
Locations
105
About this trial
This is a Phase 2 multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of lenabasum for the treatment of cystic fibrosis in patients 12 years of age or older. Approximately 415 subjects will be enrolled in this study at about 100 sites in North America, and Europe. The planned duration of treatment with study drug is 28 weeks. Study drug will be lenabasum 20 mg BID, lenabasum 5 mg BID, and placebo in a 2:1:2 ratio.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT03451045 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.